Back to Menu
1. Surgical treatment
Surgery aims for gross total resection and is the foundation for long-term survival. Hypothalamic function should be protected, and either a transcranial or endonasal transsphenoidal approach is selected according to tumor subtype and anatomy.
2. Neuronavigation and minimally invasive techniques
Navigation systems and neuroendoscopy enable precise localization and real-time guidance of resection extent, maximizing preservation of normal brain tissue.
3. Radiotherapy: an important adjuvant and alternative option
Indicated for residual disease, recurrence, or patients who are not surgical candidates. Stereotactic radiotherapy provides high precision, and proton therapy may offer advantages, particularly in children.
4. Endocrine replacement and metabolic management
Lifelong hormone replacement is often required postoperatively, including glucocorticoids and other pituitary hormones. Central diabetes insipidus, electrolyte disturbances, and hypothalamic obesity require close management.
5. Multidisciplinary collaborative model
An MDT team across multiple specialties develops individualized, longitudinal care plans spanning preoperative assessment through long-term postoperative follow-up.
6. Intracystic and interventional therapies
For large cystic tumors, cyst aspiration and intracystic drug instillation or intracavitary irradiation can control cyst refilling and slow tumor growth.
7. Molecular targeted therapy
For papillary craniopharyngioma with BRAF V600E mutation, targeted agents have demonstrated substantial efficacy and offer new therapeutic opportunities.
8. Emerging therapies and clinical research
Preclinical research suggests potential drug repurposing (e.g., antihypertensive agents). Patients may consider clinical trials to access investigational options.
9. Perioperative intensive monitoring and supportive care
ICU-level monitoring and management of complications such as diabetes insipidus and electrolyte imbalance, supported by specialized teams, improve safety and outcomes.
10. Individualized and risk-stratified strategies
Decisions should integrate age, subtype, and degree of hypothalamic adherence. In older patients, symptom control and “living with tumor” strategies may be more realistic.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although craniopharyngioma is benign, its critical location can result in lifelong endocrine dysfunction and visual impairment. Management has entered an era of minimally invasive and precision medicine. Early diagnosis and MDT-based collaboration are pivotal for tumor control, functional preservation, and improved prognosis. Patients should remain engaged and prepare for lifelong follow-up and management.
1. Surgical treatment
Surgery aims for gross total resection and is the foundation for long-term survival. Hypothalamic function should be protected, and either a transcranial or endonasal transsphenoidal approach is selected according to tumor subtype and anatomy.
2. Neuronavigation and minimally invasive techniques
Navigation systems and neuroendoscopy enable precise localization and real-time guidance of resection extent, maximizing preservation of normal brain tissue.
3. Radiotherapy: an important adjuvant and alternative option
Indicated for residual disease, recurrence, or patients who are not surgical candidates. Stereotactic radiotherapy provides high precision, and proton therapy may offer advantages, particularly in children.
4. Endocrine replacement and metabolic management
Lifelong hormone replacement is often required postoperatively, including glucocorticoids and other pituitary hormones. Central diabetes insipidus, electrolyte disturbances, and hypothalamic obesity require close management.
5. Multidisciplinary collaborative model
An MDT team across multiple specialties develops individualized, longitudinal care plans spanning preoperative assessment through long-term postoperative follow-up.
6. Intracystic and interventional therapies
For large cystic tumors, cyst aspiration and intracystic drug instillation or intracavitary irradiation can control cyst refilling and slow tumor growth.
7. Molecular targeted therapy
For papillary craniopharyngioma with BRAF V600E mutation, targeted agents have demonstrated substantial efficacy and offer new therapeutic opportunities.
8. Emerging therapies and clinical research
Preclinical research suggests potential drug repurposing (e.g., antihypertensive agents). Patients may consider clinical trials to access investigational options.
9. Perioperative intensive monitoring and supportive care
ICU-level monitoring and management of complications such as diabetes insipidus and electrolyte imbalance, supported by specialized teams, improve safety and outcomes.
10. Individualized and risk-stratified strategies
Decisions should integrate age, subtype, and degree of hypothalamic adherence. In older patients, symptom control and “living with tumor” strategies may be more realistic.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although craniopharyngioma is benign, its critical location can result in lifelong endocrine dysfunction and visual impairment. Management has entered an era of minimally invasive and precision medicine. Early diagnosis and MDT-based collaboration are pivotal for tumor control, functional preservation, and improved prognosis. Patients should remain engaged and prepare for lifelong follow-up and management.